Aldeyra Therapeutics
Open
$1.76
Prev. Close
$1.76
High
$1.77
Low
$1.76
Market Snapshot
$105.92M
-3.9
-0.94
8
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Recently from Cashu
Aldeyra Seeks FDA Feedback on Reproxalap After Multiple Complete Response Letters
Aldeyra Therapeutics (Ticker: ALDX) focuses on its dry eye disease candidate reproxalap as it seeks feedback from the FDA following three complete response letters (CRLs) questioning the efficacy of t…
Aldeyra Therapeutics Under Legal Investigation After FDA Rejection of New Drug Application
Aldeyra Therapeutics Faces Legal Scrutiny Amid FDA Setbacks Aldeyra Therapeutics, Inc. is currently at the center of an investigation by the Rosen Law Firm, which is exploring potential securities cla…
Aldeyra Therapeutics Faces Legal Challenges Following FDA Concerns About Reproxalap Efficacy
Aldeyra Therapeutics Under scrutiny: FDA Response Triggers Legal Investigations Aldeyra Therapeutics, a biopharmaceutical company focused on developing innovative therapies for ocular conditions, face…
Aldeyra Therapeutics Faces Setback as FDA Issues Complete Response Letter for Reproxalap Approval
Aldeyra Therapeutics Faces Regulatory Hurdles for Dry Eye Treatment Aldeyra Therapeutics encounters a significant setback as the FDA issues a Complete Response Letter (CRL) regarding its New Drug Appl…